Sharon Wilks joins NEXT Oncology’s phase I clinical investigation team

Kaklamani: The San Antonio Breast Cancer Symposium will focus on deescalating treatment while maintaining outcomes

The San Antonio Breast Cancer Symposium will focus on doing the same with less—less surgery, less radiation, while maintaining clinical outcomes. The symposium will take place Dec. 10-13 in San Antonio, TX.

A clinic at Fred Hutch addresses sexual health needs of patients with breast cancer
Data indicate low adherence to ASCO guideline

New data indicate that, professional guidelines notwithstanding, doctors rarely address concerns about sexual health when they treat women with cancer.

November 15, 2024

Vol.50 No.43

By Claire Marie Porter

In Brief

J. Leonard Lichtenfeld joins SpotitEarly as CMO

J. Leonard Lichtenfeld joined SpotitEarly, an Israel-based technology company transforming cancer screening by harnessing the power of artificial intelligence and dogs to detect cancer early, as chief medical officer.

November 15, 2024

Vol.50 No.43

In Brief

Fred Hutch, UW, and Seattle Children’s consortium researchers receive $1.7M from Breast Cancer Research Foundation

Six Fred Hutch/University of Washington/Seattle Children’s Cancer Consortium scientists received $1.7M in grants from Breast Cancer Research Foundation to launch or continue studies aimed at improving outcomes in breast cancer.

November 15, 2024

Vol.50 No.43

In Brief

Bertagnolli, Goldberg, Gunn, Brundage, and Theiler receive awards at Alliance fall meeting

NIH Director Monica M. Bertagnolli delivered the Charles G. Moertel Lecture at the Fall Group Meeting of the Alliance for Clinical Trials in Oncology. The meeting took place Oct. 30-Nov. 1.

November 15, 2024

Vol.50 No.43

Clinical Roundup

Phase I clinical trial of Keytruda + Lymphir for recurrent solid tumors yields positive preliminary results

Promising preliminary results from an ongoing investigator-initiated phase I clinical trial evaluating the safety and efficacy of a combined regimen of Keytrua (pembrolizumab) and Lymphir (denileukin diftitox-cxdl or E7777) in patients with recurrent solid tumors were announced.

November 15, 2024

Vol.50 No.43

Sharon Wilks joins NEXT Oncology’s phase I clinical investigation team

YOU MAY BE INTERESTED IN

Kaklamani: The San Antonio Breast Cancer Symposium will focus on deescalating treatment while maintaining outcomes

A clinic at Fred Hutch addresses sexual health needs of patients with breast cancer
Data indicate low adherence to ASCO guideline

J. Leonard Lichtenfeld joins SpotitEarly as CMO

Fred Hutch, UW, and Seattle Children’s consortium researchers receive $1.7M from Breast Cancer Research Foundation

Bertagnolli, Goldberg, Gunn, Brundage, and Theiler receive awards at Alliance fall meeting

Phase I clinical trial of Keytruda + Lymphir for recurrent solid tumors yields positive preliminary results

Renew today!

Subscriber content

Login

Sharon Wilks joins NEXT Oncology’s phase I clinical investigation team

YOU MAY BE INTERESTED IN

Kaklamani: The San Antonio Breast Cancer Symposium will focus on deescalating treatment while maintaining outcomes

A clinic at Fred Hutch addresses sexual health needs of patients with breast cancerData indicate low adherence to ASCO guideline

J. Leonard Lichtenfeld joins SpotitEarly as CMO

Fred Hutch, UW, and Seattle Children’s consortium researchers receive $1.7M from Breast Cancer Research Foundation

Bertagnolli, Goldberg, Gunn, Brundage, and Theiler receive awards at Alliance fall meeting

Phase I clinical trial of Keytruda + Lymphir for recurrent solid tumors yields positive preliminary results

Login

A clinic at Fred Hutch addresses sexual health needs of patients with breast cancer
Data indicate low adherence to ASCO guideline